Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
Steven A Nielsen,1 Marguerite B McDonald,2 Parag A Majmudar31Nielsen Eye Center, Quincy, MA, USA; 2Ophthalmic Consultants of Long Island, Lynbrook, NY, USA; 3Chicago Cornea Consultants Hoffman Estates, IL, USABackground: To evaluate the safety of besifloxacin ophthalmic suspension 0.6% when used in...
Main Authors: | Nielsen SA, McDonald MB, Majmudar PA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-01-01
|
Series: | Clinical Ophthalmology |
Online Access: | http://www.dovepress.com/safety-of-besifloxacin-ophthalmic-suspension-06-in-refractive-surgery--a11977 |
Similar Items
-
Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
by: Nielsen SA, et al.
Published: (2013-04-01) -
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
by: Silverstein BE, et al.
Published: (2012-11-01) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
by: Morris TW, et al.
Published: (2011-09-01) -
Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens
by: Comstock TL, et al.
Published: (2014-04-01) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
by: Haas W, et al.
Published: (2011-09-01)